l-carnitine with fucoxanthin Combined protective effects of oligo-fucoidan, fucoxanthin, and on the kidneys of chronic kidney disease mice 1st phorm l-carnitine w/ fucoxanthin

10, 11, 12, 14, 15, 16, 17 This animal model provides an understanding of how exogenous agents, such as PPA, can cause reversible behavioral, metabolic, neuropathological and neurophysiological changes associated with ASD

When combined, these ingredients can synergistically enhance cholinergic action through multiple, complementary, and interdependent mechanisms

Despite the well-documented positive effects of IGF-1 in the setting of PNI, the major obstacle for clinical translation remains the lack of a practical delivery system that offers tunable and sustained release of bioactive IGF-1 targeted to nerve and muscle tissue downstream of the nerve injury

doi: 10.3390/biomedicines9101284

[DOI] [PubMed] [Google Scholar] Uotila L., Koivusalo M